Thursday, November 12, 2026

Ready Capital logs massive loan losses as US commercial real estate crisis spreads to specialty lenders

Ready Capital Corporation reported severe credit deterioration across its commercial real estate and small business loan portfolios, threatening the specialty finance REIT's solvency. The crisis mirrors distress spreading through shadow banking sectors globally as rising interest rates expose aggressive lending from the low-rate era. Other non-bank lenders with similar portfolios face comparable risks.

Ready Capital logs massive loan losses as US commercial real estate crisis spreads to specialty lenders
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Ready Capital Corporation reported massive loan losses across its commercial real estate and SBA-backed small business portfolios, raising questions about the US specialty finance REIT's survival. Credit deterioration has reached levels that threaten the firm's capital base and ability to pay dividends.

The crisis reflects broader stress in commercial real estate lending worldwide. Specialty finance firms expanded aggressively during the low-rate era, funding riskier borrowers that traditional banks avoided. Rising rates now expose these credit risks across markets in North America, Europe, and Asia.

Ready Capital's core business lines show severe weakness. Small business defaults are rising in its SBA lending portfolio. Commercial real estate loans face similar pressure as office, retail, and multifamily properties struggle with higher borrowing costs and falling valuations.

The situation could trigger contagion across the specialty finance sector. Other REITs and non-bank lenders with similar loan portfolios may face comparable credit deterioration. Investors are reassessing risk across all commercial real estate lenders globally.

Regulatory scrutiny is likely to intensify. Banking regulators typically monitor specialty finance firms less closely than traditional banks. But systemic risks may prompt closer oversight in the US and other jurisdictions where shadow banking grew rapidly.

Ready Capital's options include raising emergency capital, selling assets at losses, or suspending dividends to preserve cash. None offers an easy path given current market conditions and investor skepticism toward commercial real estate.

The crisis highlights risks in shadow banking systems globally. Non-bank lenders filled gaps left by regulated banks after the 2008 financial crisis but face consequences of looser underwriting standards. Similar patterns are emerging in markets from Europe to Australia as rates remain elevated.


Sources:
1 News Report, "Ready Capital Series E declares $0.4063 dividend" (March 16, 2026)
2 News Report, "Ready Capital Ser C declares $0.3906 dividend" (March 16, 2026)
3 News Report, "Ready Capital declares $0.01 dividend" (March 16, 2026)
4 Globe Newswire, "Ready Capital Corporation Declares First Quarter 2026 Dividends" (March 13, 2026)

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com